1. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur Vaiss59:263-272, 1966
2.
2. Carmeliet E. Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. Circ Res73:857-868, 1993
3.
3. Weissenburger J, Chezalviel F, Davy JM, et al. Methods and limitations of an experimental model of long QT syndrome. J Pharmacol Meth26:23-42, 1991
4.
4. Weissenburger J, Davy JM, Chezalviel F, et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther259:871-883, 1992
5.
5. Vos MA, Verduyn SC, Gorgels AP, et al. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias, by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation91:864-872, 1995
6.
6. Verduyn SC, Vos MA, Gorgels AP, et al. The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart. J Cardiovasc Electrophysiol6:189-200, 1995
7.
7. Verduyn SC, Vos MA, Zande van der J, et al. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: Reversal by magnesium. Cardiovasc Res34:453-463, 1997
8.
8. Verduyn SC, Vos MA, Wellens HJ, et al. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired Torsade de Pointes arrhythmias. A comparison between almokalant and d-sotalol using the dog as its own control. J Am Coll Cardiol30:1575-1584, 1997
9.
9. Zande van der J, Vos MA, Fazekas T, et al. The dosedependent increase in interventricular dispersion of repolarization after ibutilide causes the transition from repetitive ectopic beats to torsade de pointes arrhythmias. Eur Heart J17 (abstract), 1997
10.
10. Vos MA, de Groot SH, Verduyn SC, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation98:1125-1135, 1998
11.
11. Verduyn SC, Vos MA, Leunissen HD, van Opstal JM, et al. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. J Cardiovasc Pharmacol33:212-222, 1999
12.
12. van Opstal JM, Vos MA, Leunissen HDM, et al. Azimilide and dofetilide produce similar electrophysiological and pro-arrhythmic effects in a canine model of Torsade de Pointes arrhythmias. Eur J Pharmacol412:67-76, 2001
13.
13. El-Sherif N, Caref EB, Yin H, et al. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res79:474-492, 1996
14.
14. Duker GD, GS L. An animal model for studying class III induced proarrhythmias in the halothane-anesthetized dog. J Am Coll Cardiol326A (abstract), 1994
15.
15. Derakhchan K, Cardinal R, Brunet S, et al. Polymorphic ventricular tachycardias induced by D-sotalol and phenylephrine in canine preparations of atrioventricular block: Initiation in the conduction system followed by spatially unstable re-entry. Cardiovasc Res38:617-630, 1998
16.
16. Weissenburger J, Noyer M, Cheymol G, et al. Electrophysiological effects of cetirizine, astemizole and Dsotalol in a canine model of long QT syndrome. Clin Exp Allergy29 (suppl 3):190-196, 1999
17.
17. Chen YJ, Hsieh MH, Chiou CW, et al. Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. J Cardiovasc Pharmacol34:237-247, 1999
18.
18. Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: Torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol11:290-304, 2000
19.
19. Antzelevitch C, Sun ZQ, Zhang ZQ, et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol28:1836-1848, 1996
20.
20. Shimizu W, Antzelevitch C. Differential effects of betaadrenergic agonists and antagonists in LQTI, LQT2, and LQT3 models of the long QT syndrome. J Am Coll Cardiol35:778-786, 2000
21.
21. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol16:276-285, 1990
22.
22. Carlsson L, Abrahamsson C, Drews L, et al. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation85:1491-1500, 1992
23.
23. Carlsson L, Drews L, Duker G, et al. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther26:1076-1080, 1993
24.
24. Carlsson L, Abrahamsson C, Andersson B, et al. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc Res27:2186-2193, 1993
25.
25. Buchanan LV, Kabell G, Brunden MN, et al. Comparative assessment of ibutilide, D-sotalol, clofilium, E-403 1, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol22:540-549, 1993
26.
26. Bril A, Gout B, Bonhomme M, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. J Pharmacol Exp Ther276:637-646, 1996
27.
27. Brooks RR, Drexler AP, Maynard AE, et al. Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. Proc Soc Exp Biol Med223:183-189, 2000
28.
28. Carlsson L, Duker G, Hondeghem L. H 345/52 A novel repolarization-delaying antiarrhythmic agent with greatly reduced proarrhythmic potential. J Am Coll Cardiol35:97A-97A, 2000
29.
29. Zabel M, Hohnloser SH, Behrens S, et al. Electrophysiologic features of torsades de pointes: Insights from a new isolated rabbit heart model. J Cardiovasc Electrophysiol8:1148-1158, 1997
30.
30. Eckardt L, Haverkamp W, Mertens H, et al. Drug-related torsades de pointes in the isolated rabbit heart: Comparison of clofilium, d,l-sotalol, and erythromycin. J Cardiovasc Pharmacol32:425-434, 1998
31.
31. Johna R, Mertens H, Haverkamp W, et al. Clofilium in the isolated perfused rabbit heart: A new model to study proarrhythmia induced by class III antiarrhythmic drugs. Basic Res Cardiol93:127-135, 1998
32.
32. D'Alonzo AJ, Zhu JL, Darbenzio RB. Effects of class III antiarrhythmic agents in an in vitro rabbit model of spontaneous torsades de pointe. Eur J Pharmacol369:57-64, 1999
33.
33. Spear JF, Moore EN. Modulation of quinidine-induced arrhythmias by temperature in perfused rabbit heart. Am J Physiol274:H817-H828, 1998
34.
34. Liu XK, Wang W, Ebert SN, et al. Female gender is a risk factor for torsades de pointes arrhythmias in an in vitro animal model. J Cardiovasc Pharmacol34:287-294, 1999
35.
35. Bauman JL, Bauermfeind RA, Hoff JV, et al. Torsade de pointes due to quinidine: Observations in 31 patients. Am Heart J107:425-430, 1984
36.
36. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol2:806-817, 1983
37.
37. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA270:2590-2597, 1993
38.
38. Liu XK, Katchman A, Drici MD, et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther285:672-679, 1998
39.
39. de Groot SHM, Vos MA, Schoenmakers M, et al. Contractile adaptations preserving cardiac output predispose the hypertrophied canine heart for delayed afterdepolarizations dependent ventricular arrhythmias. Circulation102:2145-2151, 2000
40.
40. Verduyn SC, Ramakers C, Snoep G, et al. Time course of the structural adaptations in chronic AV block dogs: Evidence for differential ventricular remodeling. Am J Physiol2001 (in press)
41.
41. Volders PG, Sipido KR, Vos MA, et al. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation98:1136-1147, 1998
42.
42. Volders PG, Sipido KR, Vos MA, et al. Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation100:2455-2461, 1999
43.
43. Winslow E, Campbell JK, Barron E. Effects of amiodarone on cardiac electrophysiology and inducibility of arrhythmias in chronically infarcted dogs: Late arrhythmias, hemodynamics, and sympatholytic actions. J Cardiovasc Pharmacol16:896-904, 1990
44.
44. Wellens HJJ, Brugada P, Abdollah H, et al. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation69:120-124, 1984
45.
45. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between dsotalol and the new antiarrhythmic drug ambasilide. Circulation90:2032-2040, 1994
46.
46. Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res37:627-635, 1998
47.
47. Kidwell GA, Gonzalez MD. Effects of flecainide and Dsotalol on myocardial conduction and refractoriness: Relation to antiarrhythmic and proarrhythmic drug effects. J Cardiovasc Pharmacol21:621-632, 1993
48.
48. Lynch JJ, Coskey LA, Montgomery DG, et al. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. Am Heart J109:949-958, 1985
49.
49. Buchanan LV, Kabell G, Turcotte UM, et al. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. J Cardiovasc Pharmacol19:256-263, 1992
50.
50. Drexler AP, Micklas JM, Brooks RR. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol28:848-855, 1996
51.
51. Zuanetti G, Corr PB. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: Evaluation using three-dimensional mapping. J Pharmacol Exp Ther256:325-334, 1991
52.
52. Nabih MA, Prcevski P, Fromm BS, et al. Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. Pacing Clin Electrophysiol16:1975-1983, 1993
53.
53. Hodeige D, Chatelain P, Manning M. SR 33589-effect on atrial fibrillation in dogs: Comparison with amiodarone. In: Hauns0 S, Kjeldsen K (eds). European section meeting: International society for heart research, Copenhagen (Denmark) June 8-11, 1994. Bologna (Italy): Monduzzi, Editore S.p.A.; pp 681-684, 1994
54.
54. Duker G, Almgren O, Carlsson L. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog (published erratum appears in J Cardiovasc Pharmacol 20(6): 1014-1015, 1992). J Cardiovase Pharmacol20:458-465, 1992
